Pfizer Inc announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA® (Meningococcal Group B ...
• Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 ...
• 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, ...
• First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line ...
GlaxoSmithKline and Innoviva, Inc announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the ...
• Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension ...
Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and ...
Swedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life therapy, ...
Swedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life therapy, ...
GSK presented new data for its meningococcal group B vaccine, Bexsero®,1 comparing safety ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
